ALLMedicine™ Hereditary Hemorrhagic Telangiectasia Center

May 11th, 2021 - Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease that manifests as vascular malformations in the brain, lung, liver, gastrointestinal tract, nasal mucosa, and skin. Diagnosis and management of HHT is guided in large par...

Apr 25th, 2021 - Pulmonary Arterial Hypertension (PAH), a rare complication of HHT is associated with poor outcome. There are no trials to date that have investigated whether pulmonary vasodilator therapy improves hemodynamics or survival in this disease. To deter...

Apr 24th, 2021 - Hereditary hemorrhagic telangiectasia (HHT) is a genetic disease characterized by vascular dysplasia. Mutations of the endoglin (ENG) gene that encodes a co-receptor of the transforming growth factor β1 signaling pathway cause type I HHT. ENG is p...

Apr 23rd, 2021 - Adrenomedullin (AM) is a vasoactive peptide mostly secreted by endothelial cells with an important role in preserving endothelial integrity.  The relationship between AM and hereditary hemorrhagic telangiectasia (HHT) is unknown. We aimed to compa...

Apr 15th, 2021 - Rapid Sequence Induction and Intubation for Patients With Hereditary Hemorrhagic Telangiectasia.|2021|Safi C,Troob S,Gudis DA,|

Sep 7th, 2020 - Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of vascular malformations (VMs). These result in chronic bleeding, acute hemorrhage, and c...

Apr 6th, 2020 - Hereditary hemorrhagic telangiectasia and liver involvement: Vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver.|2020|Silv...

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of vascular malformations (VMs). These result in chronic bleeding, acute hemorrhage, and c...

May 11th, 2021 - Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease that manifests as vascular malformations in the brain, lung, liver, gastrointestinal tract, nasal mucosa, and skin. Diagnosis and management of HHT is guided in large par...

Apr 25th, 2021 - Pulmonary Arterial Hypertension (PAH), a rare complication of HHT is associated with poor outcome. There are no trials to date that have investigated whether pulmonary vasodilator therapy improves hemodynamics or survival in this disease. To deter...

Apr 24th, 2021 - Hereditary hemorrhagic telangiectasia (HHT) is a genetic disease characterized by vascular dysplasia. Mutations of the endoglin (ENG) gene that encodes a co-receptor of the transforming growth factor β1 signaling pathway cause type I HHT. ENG is p...

Apr 23rd, 2021 - Adrenomedullin (AM) is a vasoactive peptide mostly secreted by endothelial cells with an important role in preserving endothelial integrity.  The relationship between AM and hereditary hemorrhagic telangiectasia (HHT) is unknown. We aimed to compa...

Apr 15th, 2021 - Rapid Sequence Induction and Intubation for Patients With Hereditary Hemorrhagic Telangiectasia.|2021|Safi C,Troob S,Gudis DA,|

Sep 29th, 2020 - The Second International Hereditary Hemorrhagic Telangiectasia (HHT) Guidelines were published on September 8, 2020.[1] Management of Epistaxis To reduce HHT-related epistaxis, use moisturizing topical therapies that humidify the nasal mucosa. Con...

Sep 29th, 2020 - The Second International Hereditary Hemorrhagic Telangiectasia (HHT) Guidelines were published on September 8, 2020.[1] Management of Epistaxis To reduce HHT-related epistaxis, use moisturizing topical therapies that humidify the nasal mucosa. Con...

Sep 9th, 2020 - NEW YORK (Reuters Health) - New guidelines provide updated advice on managing epistaxis and vascular malformations and new recommendations for managing gastrointestinal (GI) bleeding, anemia, pediatric care, and pregnancy and delivery. The expert ...

Sep 9th, 2020 - NEW YORK (Reuters Health) - New guidelines provide updated advice on managing epistaxis and vascular malformations and new recommendations for managing gastrointestinal (GI) bleeding, anemia, pediatric care, and pregnancy and delivery. The expert ...

Jun 17th, 2020 - Bevacizumab has shown efficacy in the treatment of hereditary hemorrhagic telangiectasia (HHT), a rare, progressive bleeding disorder for which there are currently no approved therapies. The finding comes from the InHIBIT-Bleed trial, results from...